vs
MGP INGREDIENTS INC（MGPI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是MGP INGREDIENTS INC的1.5倍（$207.3M vs $138.3M），Ultragenyx Pharmaceutical Inc.净利率更高（-62.0% vs -97.3%，领先35.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -23.5%），MGP INGREDIENTS INC自由现金流更多（$24.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -9.9%）
MGP配料公司是总部位于美国的优质蒸馏酒、特种小麦和玉米基淀粉及蛋白质配料供应商，服务食品饮料制造、餐饮及工业客户领域，为北美及部分全球市场客户提供定制化配料解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
MGPI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $138.3M | $207.3M |
| 净利润 | $-134.6M | $-128.6M |
| 毛利率 | 34.9% | — |
| 营业利润率 | -97.7% | -54.7% |
| 净利率 | -97.3% | -62.0% |
| 营收同比 | -23.5% | 25.9% |
| 净利润同比 | -220.8% | 3.5% |
| 每股收益（稀释后） | $-6.23 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $138.3M | $207.3M | ||
| Q3 25 | $130.9M | $159.9M | ||
| Q2 25 | $145.5M | $166.5M | ||
| Q1 25 | $121.7M | $139.3M | ||
| Q4 24 | $180.8M | $164.6M | ||
| Q3 24 | $161.5M | $139.5M | ||
| Q2 24 | $190.8M | $147.0M | ||
| Q1 24 | $170.6M | $108.8M |
| Q4 25 | $-134.6M | $-128.6M | ||
| Q3 25 | $15.4M | $-180.4M | ||
| Q2 25 | $14.4M | $-115.0M | ||
| Q1 25 | $-3.0M | $-151.1M | ||
| Q4 24 | $-42.0M | $-133.2M | ||
| Q3 24 | $23.9M | $-133.5M | ||
| Q2 24 | $32.1M | $-131.6M | ||
| Q1 24 | $20.6M | $-170.7M |
| Q4 25 | 34.9% | — | ||
| Q3 25 | 37.8% | — | ||
| Q2 25 | 40.1% | — | ||
| Q1 25 | 35.6% | — | ||
| Q4 24 | 41.2% | — | ||
| Q3 24 | 40.8% | — | ||
| Q2 24 | 43.6% | — | ||
| Q1 24 | 36.8% | — |
| Q4 25 | -97.7% | -54.7% | ||
| Q3 25 | 16.1% | -106.9% | ||
| Q2 25 | 14.0% | -64.8% | ||
| Q1 25 | -0.6% | -102.6% | ||
| Q4 24 | -16.8% | -74.3% | ||
| Q3 24 | 20.2% | -94.6% | ||
| Q2 24 | 22.7% | -79.1% | ||
| Q1 24 | 17.0% | -151.9% |
| Q4 25 | -97.3% | -62.0% | ||
| Q3 25 | 11.8% | -112.8% | ||
| Q2 25 | 9.9% | -69.0% | ||
| Q1 25 | -2.5% | -108.5% | ||
| Q4 24 | -23.2% | -80.9% | ||
| Q3 24 | 14.8% | -95.7% | ||
| Q2 24 | 16.8% | -89.5% | ||
| Q1 24 | 12.1% | -156.8% |
| Q4 25 | $-6.23 | $-1.28 | ||
| Q3 25 | $0.71 | $-1.81 | ||
| Q2 25 | $0.67 | $-1.17 | ||
| Q1 25 | $-0.14 | $-1.57 | ||
| Q4 24 | $-1.86 | $-1.34 | ||
| Q3 24 | $1.07 | $-1.40 | ||
| Q2 24 | $1.43 | $-1.52 | ||
| Q1 24 | $0.92 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.5M | $421.0M |
| 总债务越低越好 | $245.9M | — |
| 股东权益账面价值 | $718.4M | $-80.0M |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
| Q4 25 | $18.5M | $421.0M | ||
| Q3 25 | $13.4M | $202.5M | ||
| Q2 25 | $17.3M | $176.3M | ||
| Q1 25 | $20.1M | $127.1M | ||
| Q4 24 | $25.3M | $174.0M | ||
| Q3 24 | $20.8M | $150.6M | ||
| Q2 24 | $21.0M | $480.7M | ||
| Q1 24 | $19.5M | $112.3M |
| Q4 25 | $245.9M | — | ||
| Q3 25 | $262.3M | — | ||
| Q2 25 | $290.7M | — | ||
| Q1 25 | $290.7M | — | ||
| Q4 24 | $317.1M | — | ||
| Q3 24 | $283.6M | — | ||
| Q2 24 | $303.0M | — | ||
| Q1 24 | $294.4M | — |
| Q4 25 | $718.4M | $-80.0M | ||
| Q3 25 | $855.2M | $9.2M | ||
| Q2 25 | $841.8M | $151.3M | ||
| Q1 25 | $828.3M | $144.2M | ||
| Q4 24 | $834.2M | $255.0M | ||
| Q3 24 | $914.5M | $346.8M | ||
| Q2 24 | $894.5M | $432.4M | ||
| Q1 24 | $867.0M | $140.3M |
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | $1.4B | $1.3B |
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.31× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $24.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 17.5% | -48.6% |
| 资本支出强度资本支出/营收 | 3.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $76.0M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $29.1M | $-99.8M | ||
| Q3 25 | $36.1M | $-91.4M | ||
| Q2 25 | $11.7M | $-108.3M | ||
| Q1 25 | $44.7M | $-166.5M | ||
| Q4 24 | $28.8M | $-79.3M | ||
| Q3 24 | $43.9M | $-67.0M | ||
| Q2 24 | $5.0M | $-77.0M | ||
| Q1 24 | $24.6M | $-190.7M |
| Q4 25 | $24.3M | $-100.8M | ||
| Q3 25 | $27.6M | $-92.7M | ||
| Q2 25 | $-557.0K | $-110.7M | ||
| Q1 25 | $24.8M | $-167.8M | ||
| Q4 24 | $10.4M | $-79.5M | ||
| Q3 24 | $24.5M | $-68.6M | ||
| Q2 24 | $-1.4M | $-79.0M | ||
| Q1 24 | $-2.4M | $-193.9M |
| Q4 25 | 17.5% | -48.6% | ||
| Q3 25 | 21.1% | -58.0% | ||
| Q2 25 | -0.4% | -66.5% | ||
| Q1 25 | 20.4% | -120.5% | ||
| Q4 24 | 5.8% | -48.3% | ||
| Q3 24 | 15.2% | -49.2% | ||
| Q2 24 | -0.7% | -53.7% | ||
| Q1 24 | -1.4% | -178.2% |
| Q4 25 | 3.5% | 0.5% | ||
| Q3 25 | 6.5% | 0.8% | ||
| Q2 25 | 8.4% | 1.5% | ||
| Q1 25 | 16.4% | 1.0% | ||
| Q4 24 | 10.1% | 0.1% | ||
| Q3 24 | 12.0% | 1.2% | ||
| Q2 24 | 3.3% | 1.4% | ||
| Q1 24 | 15.8% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.84× | — | ||
| Q2 24 | 0.15× | — | ||
| Q1 24 | 1.19× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGPI
| Branded Spirits | $63.4M | 46% |
| Ingredient Solutions | $31.3M | 23% |
| Specialty Wheat Starches | $16.8M | 12% |
| Mid Spirits | $16.1M | 12% |
| Other Branded Spirits | $8.0M | 6% |
| Commodity Wheat Starch | $2.3M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
